Medical Crossfire®: DLL3-Directed Therapies in Small Cell Lung Cancer—A Nursing-Centered Approach to a New Era of Care

Activity Overview

Delta-like ligand 3 (DLL3) is reshaping the treatment landscape for small cell lung cancer (SCLC), one of the most aggressive and rapidly relapsing malignancies. As a highly actionable therapeutic target, DLL3 has become a central focus of innovation with the FDA approval of the DLL3-directed bispecific T-cell engager tarlatamab and the ongoing development of other DLL3-targeted strategies. These breakthroughs bring new hope for patients, but also introduce distinct therapy-specific toxicities, including cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and hematologic adverse events that demand specialized nursing expertise.

This CE-certified Medical Crossfire® symposium convenes a multidisciplinary panel of experts in SCLC to translate evolving DLL3 science into practical, nursing-centered strategies for real-world care. Through concise didactic updates, case-based debates, and interactive discussions, the faculty will deliver actionable insights on adverse-event recognition and management, triage and workflow optimization, outpatient monitoring and telehealth follow-up, and guideline-informed step-up dosing. This dynamic program equips oncology nurses to confidently and safely implement DLL3-targeted therapies across diverse practice settings.

This educational activity is an archive of the live virtual symposium held on May 13, 2026.

Target Audience

This educational activity is directed toward oncology nurses, nurse practitioners, and other health care providers who manage patients with SCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the unique biology of DLL3 in SCLC and its rationale as a therapeutic target
• Describe clinical efficacy, safety profiles, and mechanisms of DLL3-targeted therapies
• Identify strategies to monitor, recognize, and manage specific adverse events associated with DLL3 therapies
• Implement effective nursing interventions and patient education approaches for novel DLL3-targeted therapies in multicenter care settings

Learning Objectives for Pharmacists

• Explain the unique biology of DLL3 in SCLC and its rationale as a therapeutic target, and discuss how DLL3 expression informs the use of DLL3-directed therapies in practice
• Describe the clinical efficacy, safety profiles, and mechanisms of DLL3-targeted therapies and interpret key trial data relevant to pharmacy practice in SCLC
• Identify strategies to monitor, recognize, and manage specific adverse events associated with DLL3-targeted therapies and describe the pharmacist’s role in creating and implementing evidence-based monitoring, premedication, and mitigation protocols